Lung transplantation in Australia, 1986–2018: more than 30 years in the making

Paraskeva, Miranda A; Levin, Kovi C; Westall, Glen P; Snell, Gregory I

doi:10.5694/mja17.00909

Topics

Respiratory tract diseases

Summary

Lung transplantation in Australia is 32 years old in 2018. From its early infancy in 1986, it continues to evolve and is internationally recognised as demonstrating world’s best practices in organ donation, utilisation and transplantation procedures.
Over the past decade, transplant numbers have increased substantially due to innovations in donor procurement, such as donation after circulatory death, the use of ex vivo lung perfusion, extended criteria and organ utilisation, with more than 200 lung transplants undertaken in Australia annually. Parallel to this, lung transplant outcomes have continued to improve.
While the management of lung transplant recipients is heavily dependent on a tertiary care paradigm, this model is well developed and has been extremely successful, with Australian outcomes exceeding those of the International Society for Heart and Lung Transplantation Registry at all time points.

1 Alfred Hospital, Melbourne, VIC
2 Monash University, Melbourne, VIC

Correspondence: m.paraskeva@alfred.org.au

Competing interests:

No relevant disclosures

1. Hardy JD, Webb WR, Dalton ML Jr, Walker GR Jr. Lung homotransplantation in man. JAMA 1963; 186: 1065-1074.
2. Borel JF, Feurer C, Gubler HU, Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976; 6: 468-475.
3. Reitz BA, Wallwork JL, Hunt SA, et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 1982; 306: 557-564.
4. Toronto Lung Transplant Group. Unilateral lung transplantation for pulmonary fibrosis. N Engl J Med 1986; 314: 1140-1145.
5. Cooper JD, Patterson GA, Grossman R, Maurer J. Double-lung transplant for advanced chronic obstructive lung disease. Am Rev Respir Dis 1989; 139: 303-307.
6. Tait BD. More than a footnote: the story of organ transplantation in Australia and New Zealand. Melbourne: Australian Scholarly, 2012.
7. Chambers DC, Yusen RD, Cherikh WS, et al; The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Lung And Heart-Lung Transplantation Report — 2017; Focus Theme: Allograft ischemic time. J Heart Lung Transplant 2017; 36: 1047-1059.
8. Australia and New Zealand Cardiothoracic Organ Transplant Registry. 2016 annual report. ANZCOTR: Sydney. 2016. http://www.anzcotr.org.au/ (viewed Aug 2017).
9. Organ and Tissue Authority. National program. http://www.donatelife.gov.au/about-us/national-reform-programme (viewed Aug 2017).
10. Organ and Tissue Authority. Australian donation and transplantation activity report 2016. Canberra: OTA, 2016. http://www.donatelife.gov.au/sites/default/files/Australian%20Donation%20and%20Transplantation%20Activity%20Report%202016.pdf (viewed Aug 2017).
11. Levin K, Kotecha S, Westall G, Snell G. How can we improve the quality of transplantable lungs? Expert Rev Respir Med 2016: 1-7.
12. Snell GI, Westall GP, Oto T. Donor risk prediction: how ‘extended’ is safe? Curr Opin Organ Transplant 2013; 18: 507-512.
13. Australia and New Zealand Organ Donation Registry. 2016 annual report. Adelaide: ANZOD, 2016. http://www.anzdata.org.au/anzod/v1/reports.html (viewed Aug 2017).
14. Kootstra G, Daemen JH, Oomen AP. Categories of non-heart-beating donors. Transplant Proc 1995; 27: 2893-2894.
15. Cypel M, Levvey B, Van Raemdonck D, et al. International Society for Heart and Lung Transplantation Donation After Circulatory Death Registry report. J Heart Lung Transplant 2015; 34: 1278-1282.
16. Levvey BJ, Harkess M, Hopkins P, et al. Excellent clinical outcomes from a national donation-after-determination-of-cardiac-death lung transplant collaborative. Am J Transplant 2012; 12: 2406-2413.
17. Rakhra SS, Opdam HI, Gladkis L, et al. Untapped potential in Australian hospitals for organ donation after circulatory death. Med J Aust 2017; 207: 294-301. <MJA full text>
18. Transplantation Society of Australia and New Zealand. Organ transplantation from deceased donors: consensus statement on eligibility criteria and allocation protocols. Sydney: TSANZ, 2011. http://www.donatelife.gov.au/sites/default/files/files/TSANZ_Consensus_Statement_V1_1.pdf (viewed Aug 2017).
19. Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014 – an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2015; 34: 1-15.
20. Singer JP, Diamond JM, Gries CJ, et al. Frailty phenotypes, disability, and outcomes in adult candidates for lung transplantation. Am J Respir Crit Care Med 2015; 192: 1325-1334.
21. Wilson ME, Vakil AP, Kandel P, et al. Pretransplant frailty is associated with decreased survival after lung transplantation. J Heart Lung Transplant 2016; 35: 173-178.
22. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE–5-a population-based study. Lancet Oncol 2014; 15: 23-34.
23. Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA 2006; 296: 2823-2831.
24. Mollberg NM, Farjah F, Howell E, et al. Impact of primary caregivers on long-term outcomes after lung transplantation. J Heart Lung Transplant 2015; 34: 59-64.
25. Castleberry AW, Bishawi M, Worni M, et al. Medication nonadherence after lung transplantation in adult recipients. Ann Thorac Surg 2017; 103: 274-280.
26. Butler JA, Roderick P, Mullee M, et al. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation 2004; 77: 769-776.
27. Goldfarb SB, Levvey BJ, Cherikh WS, et al, Registry of the International Society for Heart and Lung Transplantation: Twentieth Pediatric Lung and Heart-Lung Transplantation Report — 2017; Focus Theme: Allograft ischemic time. J Heart Lung Transplant 2017; 36: 1070-1079.
28. Casswell GK, Pilcher DV, Martin RS, et al. Buying time: the use of extracorporeal membrane oxygenation as a bridge to lung transplantation in pediatric patients. Pediatr Transplant 2013; 17: E182-188.
29. Keating DT, Marasco SF, Negri J, et al. Long-term outcomes of cadaveric lobar lung transplantation: helping to maximize resources. J Heart Lung Transplant 2010; 29: 439-444.
30. Paraskeva MA, Edwards LB, Levvey B, et al. Outcomes of adolescent recipients after lung transplantation: an analysis of the International Society for Heart and Lung Transplantation Registry. J Heart Lung Transplant 2018; 37: 323-331.
31. Lowery E, Adams W, Grim S, et al. Increased risk of PTLD in lung transplant recipients with cystic fibrosis. J Cystic Fibrosis 2017; 16: 727-734.
32. Sundaresan S, Trachiotis GD, Aoe M, et al. Donor lung procurement: assessment and operative technique. Ann Thorac Surg 1993; 56: 1409-1413.
33. Orens JB, Boehler A, de Perrot M, et al. A review of lung transplant donor acceptability criteria. J Heart Lung Transplant 2003; 22: 1183-1200.
34. Kotloff RM, Blosser S, Fulda GJ, et al. Management of the potential organ donor in the ICU: Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations consensus statement. Crit Care Med 2015; 43: 1291-1325.
35. Bansal R, Esan A, Hess D, et al. Mechanical ventilatory support in potential lung donor patients. Chest 2014; 146: 220-227.
36. Angel LF, Levine DJ, Restrepo MI, et al. Impact of a lung transplantation donor-management protocol on lung donation and recipient outcomes. Am J Respir Crit Care Med 2006; 174: 710-716.
37. Pratschke J, Wilhelm MJ, Kusaka M, et al. Brain death and its influence on donor organ quality and outcome after transplantation. Transplantation 1999; 67: 343-348.
38. Mascia L, Pasero D, Slutsky AS, et al. Effect of a lung protective strategy for organ donors on eligibility and availability of lungs for transplantation: a randomized controlled trial. JAMA 2010; 304: 2620-2627.
39. Kirschbaum CE, Hudson S. Increasing organ yield through a lung management protocol. Prog Transplant 2010; 20: 28-32.
40. Noiseux N, Nguyen BK, Marsolais P, et al. Pulmonary recruitment protocol for organ donors: a new strategy to improve the rate of lung utilization. Transplant Proc 2009; 41: 3284-3289.
41. Eberlein M, Permutt S, Chahla MF, et al. Lung size mismatch in bilateral lung transplantation is associated with allograft function and bronchiolitis obliterans syndrome. Chest 2012; 141: 451-460.
42. Eberlein M, Reed RM, Permutt S, et al. Parameters of donor-recipient size mismatch and survival after bilateral lung transplantation. J Heart Lung Transplant 2012; 31: 1207-1213. e7.
43. Borro JM, Sole A, De la Torre M, et al. Steroid withdrawal in lung transplant recipients. Transplant Proc 2005; 37: 3991-3993.
44. Le Page AK, Jager MM, Kotton CN, et al. International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines. Transplantation 2013; 95: 1455-1460.
45. Paraskeva M, Bailey M, Levvey BJ, et al. Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant 2011; 11: 2190-2196.
46. Westall GP, Cristiano Y, Peleg A, et al. A study of QuantiFERON-CMV-directed CMV prophylaxis versus standard-of-care to reduce late CMV reactivation following lung transplantation. J Heart Lung Transplant 2017; 36: S200-S201.
47. Langer D, Burtin C, Schepers L, et al. Exercise training after lung transplantation improves participation in daily activity: a randomized controlled trial. Am J Transplant 2012; 12: 1584-1592.
48. Ihle F, Neurohr C, Huppmann P, et al. Effect of inpatient rehabilitation on quality of life and exercise capacity in long-term lung transplant survivors: a prospective, randomized study. J Heart Lung Transplant 2011; 30: 912-919.
49. Belloli EA, Wang X, Murray S, et al. Longitudinal forced vital capacity monitoring as a prognostic adjunct after lung transplantation. Am J Respir Crit Care Med 2015; 192: 209-218.
50. Sato M, Waddell TK, Wagnetz U, et al. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. J Heart Lung Transplant 2011; 30: 735-742.

Online responses are no longer available. Please refer to our instructions for authors page for more information.